Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Gastrointestinal Stromal Tumors 4Colonic Neoplasms 4Carcinoma, Hepatocellular 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Rectal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sarcoma 1Rhabdomyosarcoma 1Renal Insufficiency 1Physician Education 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Noonan Syndrome 6 1Metastatic Pancreatic Adenocarcinoma 1Melanoma 1Liver Neoplasms 1Liposarcoma 1Insulinoma 1

Interventions

Gemcitabine 4pembrolizumab 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 24-fluorobenzoyl-TN-14003 2regorafenib 1olaparib 1irinotecan sucrosofate 1ibrutinib 1adavosertib 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Drug Therapy 1Docetaxel 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Pancreatic Adenocarcinoma × regorafenib × Clear all
NCT02383433 2023-10-23

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 8 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡